Citations

Clear

37 citation(s) found for "Sarma, D".

S1634 Metabolic Healthy Obesity in Elderly Patients Hospitalized With Colorectal Cancer Showing Paradoxical Association With Composite in Hospital Outcomes: Insights from National Inpatient Sample 2019
Nayeem, Mohammed Mustafa, Raza, Syed Mohammad Moosi, Alvi, Ali Tariq, Lakhanpal, Samridhi , Thugu, Thanmai Reddy, Atwal, Siddharth Arjun, Parisapogu, Anusha, Palepu, Sushrut Sarma, Amini, Masoud , Acherjee, Trishna , Desai, Rupak

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S1225-S1225

10.14309/01.ajg.0000956176.73357.5b Get It

S815 Impact of Cannabis Use Disorder on In-Hospital Mortality in Geriatric Population Hospitalized With Gastrointestinal Hemorrhage: A National Population Based Analysis
Alvi, Ali Tariq, Raza, Syed Mohammad Moosi, Thugu, Thanmai Reddy, Lakhanpal, Samridhi , Nayeem, Mohammed Mustafa, Parisapogu, Anusha, Palepu, Sushrut Sarma, Acherjee, Trishna , Atwal, Siddharth Arjun, Raza, Syed Mohammad Moosi, Amini, Masoud, Desai, Rupak

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S601-S602

10.14309/01.ajg.0000952900.47716.48 Get It

Changes in Doppler‐Derived Kidney Venous Flow and Adverse Cardiorenal Outcomes in Patients With Heart Failure
Husain‐Syed, Faeq , Viehman, Jason K., Vaughan, Lisa E. , Bauer, Pascal , Gall, Henning , Tello, Khodr , Richter, Manuel J. , Yogeswaran, Athiththan , Romero‐González, Gregorio , Rosner, Mitchell H. , Aßmus, Birgit , Seeger, Werner , Birk, Horst‐Walter, Singam, N Sarma V , Vaughan, Lisa , Gall, Henning , Tello, Khodr , Yogeswaran, Athiththan , Romero-González, Gregorio , Ghofrani, Hossein Ardeschir , Seeger, Werner , Kashani, Kianoush B , Husain-Syed, Faeq , Singam, Narayana Sarma V. , Ronco, Claudio , Ghofrani, Hossein Ardeschir , Kashani, Kianoush

Mayo Clinic

Journal of the American Heart Association | August 14, 2023 | Volume: 12 | Issue: 16 | Pages: No page available

10.1161/jaha.123.030145 | PMID 37577933 Get It

Background The impact of changes in Doppler‐derived kidney venous flow in heart failure (HF) is not well studied. We aimed to investigate the association of Doppler‐derived kidney venous stasis index (KVSI) and intrakidney venous‐flow (IKVF) patterns with adverse cardiorenal outcomes in patients with HF. Methods and Results In this observational cohort study, consecutive inpatients with HF referred to a nephrologist because of a history of diuretic resistance and abnormal kidney function (n=216) underwent spectral kidney assessments after admission (Doppler 1) and 25 to 35 days later (Doppler 2) to identify IKVF patterns (continuous/pulsatile/biphasic/monophasic) and KVSI levels. Cox proportional hazard regression models were used to evaluate the associations between KVSI/IKVF patterns at Doppler 1 as well as changes from Doppler 1 to Doppler 2 and risk of cardiorenal events up to 18 months after admission. Worsening HF or death occurred in 126 patients. Both baseline KVSI (hazard ratio [HR], 1.49 [95% CI, 1.37–1.61] per 0.1‐unit increase) and baseline IKVF pattern (HR, 2.47 [95% CI, 2.01–3.04] per 1 pattern severity increase) were significantly associated with worsening HF/death. Increases in both KVSI and IKVF pattern severity from Doppler 1 to 2 were also associated with an increased risk of worsening HF/death (HR, 3.00 [95% CI, 2.08–4.32] per 0.1‐unit increase change; and HR, 6.73 [95% CI, 3.27–13.86] per 1 pattern increase in severity change, respectively). Similar results were observed for kidney outcomes. Conclusions Baseline kidney venous flow predicted adverse cardiorenal events, and inclusion of serial kidney venous flow in cardiorenal risk stratification could facilitate clinical decision‐making for patients with HF. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03039959.
Cardiogenic shock: a major challenge for the clinical trialist
Sarma, Dhruv , Soussi, Sabri , Jentzer, Jacob C.

Mayo Clinic

Current Opinion in Critical Care | June 20, 2023 | Volume: 29 | Issue: 4 | Pages: 371-380

10.1097/mcc.0000000000001066 | PMID 37338937 Get It

Purpose of review Cardiogenic shock (CS) results in persistently high short-term mortality and a lack of evidence-based therapies. Several trials of novel interventions have failed to show an improvement in clinical outcomes despite promising preclinical and physiologic principles. In this review, we highlight the challenges of CS trials and provide suggestions for the optimization and harmonization of their design. Recent findings CS clinical trials have been plagued by slow or incomplete enrolment, heterogeneous or nonrepresentative patient cohorts, and neutral results. To achieve meaningful, practice-changing results in CS clinical trials, an accurate CS definition, a pragmatic staging of its severity for appropriate patient selection, an improvement in informed consent process, and the use of patient-centered outcomes are required. Future optimizations include the use of predictive enrichment using host response biomarkers to unravel the biological heterogeneity of the CS syndrome and identify subphenotypes most likely to benefit from individualized treatment to allow a personalized medicine approach. Summary Accurate characterization of CS severity and its pathophysiology are crucial to unravel heterogeneity and identify the patients most likely to benefit from a tested treatment. Implementation of biomarker-stratified adaptive clinical trial designs (i.e., biomarker or subphenotype-based therapy) might provide important insights into treatment effects.
Abstract 127: Urine Output And Mortality In Patients Resuscitated From Out Of Hospital Cardiac Arrest
Sarma, Dhruv , Kashani, Kianoush , Jentzer, Jacob C.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.127 Get It

Background: Urine output (UO) measurement utility after out-of-hospital cardiac arrest (OHCA) survivors who undergo targeted temperature management (TTM) is not well understood. Methods: We included 247 comatose adult patients who underwent TTM after OHCA between 2007 and 2017 and excluded those on maintenance dialysis. Groups were defined based on mean hourly UO during the first 24 hours: Group 1 (<0.5 ml/kg/hr, n=73), Group 2 (0.5-1 ml/kg/hr, n=81) and Group 3 (>1 ml/kg/hr, n=93). Kidney Disease: Improving Global Outcomes (KDIGO) serum creatinine criteria were used to define and stage acute kidney injury (AKI). Multivariable analysis was used to evaluate in-hospital mortality. Results: In-hospital mortality decreased as 24-hour mean UO increased (56.2% [41/73] vs 29.6% [24/81] vs 18.3% [17/93] in Groups 1, 2 and 3, respectively; adjusted OR 0.93 per 0.1 ml/kg/h higher, 95% CI 0.87-0.99, p = 0.03), and UO < 0.5 ml/kg/hr was strongly associated with in-hospital mortality (adjusted OR 4.2 [1.6-10.8], p=0.003). In-hospital mortality varied by the KDIGO stage and UO group (Figure), lowest in KDIGO stage 0 and highest in KDIGO stage 3. Both UO (adjusted OR 0.92 per 0.1 ml/kg/h higher, p = 0.002) and KDIGO stage (adjusted OR 1.62 per each stage, p = 0.002) were associated with in-hospital mortality when included in the same model. Among patients with KDIGO stage 0, lower UO portended higher mortality (Figure). Likewise, among patients with low UO (group 1), a higher KDIGO stage predicted higher mortality. Conclusion: Amongst OHCA survivors undergoing TTM, higher UO is incrementally associated with lower in-hospital mortality. The lowest mortality was observed at UO >=1 ml/kg/h, suggesting this as a target for resuscitation in OHCA patients undergoing TTM. Low UO remains associated with in-hospital mortality even when accounting for AKI by creatinine criteria, suggesting that oliguria is a more sensitive prognostic marker in the early post-OHCA phase.
Abstract 10860: Limb and Cardiovascular Event Risk in Type 1 and 2 Diabetic Patients With Peripheral Artery Disease
Girardo, Marlene , Sarma, Dhruv , Wennberg, Paul W. , Liedl, David , Shamoun, Fadi , Sykora, Daniel , Firth, Christine , Tseng, Andrew S.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.10860 Get It

Introduction: Peripheral artery disease (PAD) is a risk factor for adverse limb events (LE) and cardiovascular events (CVE) that often coexists with type 1 (T1) and type 2 (T2) diabetes mellitus (DM), which differ mechanistically. There is a paucity of data on comparative risk of LE and CVE in T1DM and T2DM patients with PAD. Methods: We queried our database of 40,144 patients ≥18y old who underwent ankle brachial index (ABI) measurement from 01/1996-02/2020. We isolated patients with T1DM or T2DM and with PAD diagnosed by ABI (low [<1.0] or elevated [>1.4]). We retrieved demographics including hemoglobin A1c (A1c). Primary outcomes were LE (critical limb ischemia or vascular amputation) and CVE (myocardial infarction or ischemic stroke). All-cause mortality was a secondary outcome. Multivariable Cox proportional regression yielded hazard ratios (HR) with 95% confidence intervals (CI) after adjusting for age, sex, A1c, hypertension, hyperlipidemia, coronary artery disease (CAD), chronic kidney disease (CKD), and tobacco use. Results: Our study found 9,271 patients with PAD and DM (36% T1DM, 64% T2DM) with median follow-up time 34 mo (interquartile range [IQR] 85 mo). T1DM patients were younger than T2DM (mean age 67 vs 70y), with higher median A1c (7.7 [IQR 1.9] vs 6.7% [IQR 1.6]), and higher prevalence of hypertension, hyperlipidemia, CAD, and CKD. Antiplatelet and statin use did not differ. Elevated ABI was more common in T1DM (47 vs 27%). LE occurred in 23% and CVE in 12% of patients. LE risk was higher in T1DM patients than T2DM (HR 1.59[95% CI 1.45,1.74], p<0.0001), but CVE and all-cause mortality did not differ significantly. Conclusions: PAD patients with T1DM had a higher LE risk than those with T2DM, even after adjustment for A1c and pertinent risk factors, but CVE risk and all-cause mortality were equivocal. These data suggest a potential role for more intensive LE risk modification in PAD patients with T1DM, but further investigation is needed to minimize limb morbidity.
Urine Output and Mortality in Patients Resuscitated from out of Hospital Cardiac Arrest
Sarma, Dhruv , Jentzer, Jacob C. , Jentzer, Jacob C , Tabi, Meir , Rabinstein, Alejandro A. , Kashani, Kianoush

Mayo Clinic

Journal of Intensive Care Medicine | January 23, 2023 | Volume: 38 | Issue: 6 | Pages: 544-552

10.1177/08850666221151014 | PMID 36683431 Get It

Background Limited data exist regarding urine output (UO) as a prognostic marker in out-of-hospital-cardiac-arrest (OHCA) survivors undergoing targeted temperature management (TTM). Methods We included 247 comatose adult patients who underwent TTM after OHCA between 2007 and 2017, excluding patients with end-stage renal disease. Three groups were defined based on mean hourly UO during the first 24 h: Group 1 (<0.5 mL/kg/h, n = 73), Group 2 (0.5−1 mL/kg/h, n = 81) and Group 3 (>1 mL/kg/h, n = 93). Serum creatinine was used to classify acute kidney injury (AKI). The primary and secondary outcomes respectively were in-hospital mortality and favorable neurological outcome at hospital discharge (modified Rankin Scale [mRS]<3). Results In-hospital mortality decreased incrementally as UO increased (adjusted OR 0.9 per 0.1 mL/kg/h higher; p = 0.002). UO < 0.5 mL/kg/h was strongly associated with higher in-hospital mortality (adjusted OR 4.2 [1.6−10.8], p = 0.003) and less favorable neurological outcomes (adjusted OR 0.4 [0.2−0.8], p = 0.007). Even among patients without AKI, lower UO portended higher mortality (40% vs 15% vs 9% for UO groups 1, 2, and 3 respectively, p < 0.001). Conclusion Higher UO is incrementally associated with lower in-hospital mortality and better neurological outcomes. Oliguria may be a more sensitive early prognostic marker than creatinine-based AKI after OHCA.
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M. , Berg, David D. , Bohula, Erin A. , Baird-Zars, Vivian M., Barnett, Christopher F. , Barsness, Gregory W. , Chaudhry, Sunit‐Preet , Daniels, Lori B. , Diepen, Sean van , Goldfarb, Michael , Katz, Jason N. , Kenigsberg, Benjamin B. , Lawler, Patrick R. , Miller, P. Elliott , Papolos, Alexander , Park, Jeong‐Gun , Prasad, Rajnish, Teuteberg, Jeffrey J. , Investigators, on behalf of the CCCTN, Goldfarb, Michael , van Diepen, Sean , Goldfarb, Michael , Jentzer, Jacob C , Lawler, Patrick , Miller, P Elliott , Potter, Brian J , Singam, N Sarma V , Solomon, Michael A , Teuteberg, Jeffrey J , Morrow, David A , Goldfarb, Michael , Daniels, Lori B , Bohula, Erin A , Berg, David , Patel, Siddharth M , Ghafghazi, Shahab , Jentzer, Jacob C. , Prasad, Rajnish, Singam, Narayana Sarma V. , Sinha, Shashank S , Solomon, Michael A. , Morrow, David A. , Investigators, on behalf of the CCCTN

Mayo Clinic

Circulation: Heart Failure | December 2, 2022 | Volume: 16 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.122.009714 | PMID 36458542 Get It

Background: Algorithmic application of the 2019 Society of Cardiovascular Angiography and Intervention (SCAI) shock stages effectively stratifies mortality risk for patients with cardiogenic shock. However, clinician assessment of SCAI staging may differ. Moreover, the implications of the 2022 SCAI criteria update remain incompletely defined. Methods: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units (CICUs). Between 2019 and 2021, participating centers (n=32) contributed at least a 2-month snapshot of consecutive medical CICU admissions. In-hospital mortality was assessed across 3 separate staging methods: clinician assessment, Critical Care Cardiology Trials Network algorithmic application of the 2019 SCAI criteria, and a revision of the Critical Care Cardiology Trials Network application using the 2022 SCAI criteria. Results: Of 9612 admissions, 1340 (13.9%) presented with cardiogenic shock with in-hospital mortality of 35.2%. Both clinician and algorithm-based staging using the 2019 SCAI criteria identified a stepwise gradient of mortality risk (stage C–E: 19.0% to 83.7% and 14.6% to 52.2%, respectively; P trend <0.001 for each). Clinician assignment of SCAI stages identified higher risk patients compared with algorithm-based assignment (stage D: 49.9% versus 29.3%; stage E: 83.7% versus 52.2%). Algorithmic application of the 2022 SCAI criteria, with incorporation of the vasoactive-inotropic score, more closely approximated clinician staging (mortality for stage C-E: 21.9% to 70.5%; P trend <0.001). Conclusions: Both clinician and algorithm-based application of the 2019 SCAI stages identify a stepwise gradient of mortality risk, although clinician-staging may better allocate higher risk patients into advanced SCAI stages. Updated algorithmic staging using the 2022 SCAI criteria and vasoactive-inotropic score further refines risk stratification.
Pulmonary vein stenosis – ballooning vs. stenting: a systematic review and meta-analysis
Almakadma, Abdul H., Sarma, D, Alkhouli, Mohamad , Packer, Douglas L. , Holmes, David R. , Simard, Trevor , Hassett, Leslie C. , Alkhouli, Mohamad

Mayo Clinic

European Heart Journal | October 15, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.2075 Get It

Abstract Background Pulmonary vein stenosis (PVS), which is often unrecognized, may arise from a variety of conditions resulting in major morbidity and mortality. In some patients, pharmacological therapy may help but more often in advance stages, mechanical treatment must be considered. Transcatheter approaches, both balloon angioplasty (BA) and stent implantation have been applied. While both may be effective, they continue to be limited by restenosis. Herein, we compare the outcomes following BA and stenting for PVS. Purpose PVS presents a challenge for both diagnosis and therapy, with BA and stenting being primarily limited by restenosis. Stenting is performed in most cases and is associated with improved patency rates. Historical comparisons of BA and stenting for PVS have yielded similar results. Our analysis incorporates more conventional studies (2010–2021) and provides a larger stent (N=361) versus BA (N=229) contemporary analysis of the current state of PV intervention practice. Methods From January 1, 2010 to August 2, 2021, studies, limited to English language and humans, were assessed in Ovid MEDLINE®, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Two independent reviewers screened articles including those in which balloon angioplasty or stenting was performed for pulmonary vein stenosis with reporting of restenosis outcomes and data was independently extracted. Systematic review was performed, and overall restenosis rates were reported across all included studies. Meta-analysis was then performed using RevMan 5.4 assessing rates of restenosis and restenosis requiring repeat intervention. Results Our systematic review yielded 34 studies reporting on BA and/or stenting for PVS. Of these, 7 studies (1–7), treating a total of 343 patients with 590 PV interventions (229 BA and 361 Stents) reported restenosis rates with mean follow-up ranging from 10 to 60 months. Stenting was associated with a lower risk of restenosis compared to balloon angioplasty [risk ratio 0.35, 95% CI (0.18, 0.64), p=0.0008] (Figure 1). Restenosis requiring repeat intervention was reported in 5 studies, including 303 patients with 502 PV interventions (160 BA and 342 Stents) with stenting similarly associated with a lower risk of restenosis requiring re-intervention [risk ratio 0.34, 95% CI (0.16, 0.72), p=0.005]. Conclusion Stenting for pulmonary vein stenosis is associated with reduced risk of restenosis and re-intervention as compared to balloon angioplasty. Funding Acknowledgement Type of funding sources: None.
Cardiovascular Mechanisms of Exercise Intolerance in Older Patients with Heart Failure
Fleg, Jerome L. , Singam, Narayana Sarma V. , Tabi, Meir

Mayo Clinic

Reviews in Cardiovascular Medicine | September 16, 2022 | Volume: 23 | Issue: 9 | Pages: No page available

10.31083/j.rcm2309313 | PMID 39077720 Get It

Exercise intolerance, measured by peak oxygen consumption (V̇O2), is a hallmark feature of heart failure (HF). The effect is compounded in the elderly HF patient by aging-associated changes such as a reduction in lean muscle mass, an increase in adiposity, and a reduction in maximal heart rate and peripheral blood flow with exercise. There is a non-linear reduction in peak V̇O2 with age that accelerates in the later decades of life. Peak V̇O2 is further reduced due to central and peripheral maladaptation from HF. Central mechanisms include impaired peak heart rate, stroke volume, contractility, increased filling pressures, and a blunted vasodilatory response. Peripheral mechanisms include endothelial dysfunction, reduced blood flow to muscles, and impaired skeletal muscle oxidative capacity. This review presents a focused update on mechanisms leading to impaired aerobic capacity in older HF patients.